EPCAM and neoplasm: In order to capitalise on the ability of antibodies to specifically target tumour cells, as well as to produce an efficacious therapeutic, the next step in developing EpCAM as a target for enhanced cytotoxicity has been to combine antibodies with cytotoxic drugs [1,29].